Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma
NCT04899427Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04899427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899427.